Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Q Biomed Inc (OP: QBIO )

1.050 USD UNCHANGED
Streaming Delayed Price Updated: 4:06 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.050
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.050
Today's Range 1.050 - 1.050
52wk Range 0.9001 - 3.000
Shares Outstanding 13,974,784
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Proactive news headlines including Algernon Pharmaceuticals, Benchmark Metals, Imagine AR Inc and Q BioMed Inc
Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: 
From GlobeNewswire News Releases
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Organization for urology private practice... 
From PR Newswire

Performance

YTD
+8.25%
+8.25%
1 Month
+5.00%
+5.00%
3 Month
-4.55%
-4.55%
6 Month
-24.46%
-24.46%
1 Year
-62.77%
-62.77%

More News

Read More
Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
From PR Newswire
Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan
From PR Newswire
Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment
From PR Newswire
Q BioMed Updates Shareholders at Year End
From PR Newswire
Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium
From PR Newswire
Q BioMed Inc. Discusses Revenue Potential of International Commercialization and Expansion of Strontium89 with The Stock Day Podcast
From Newsfile Corp News Releases
Q BioMed, Inc. CEO Discusses Recently Announced International Market Authorizations and Expansion in to South and Central America and Asia for Q BioMed’s Strontium89, its FDA Approved Drug for the Non
From GlobeNewswire News Releases
Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe
From PR Newswire
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.